MARQUEE collapses on tivantinib in NSCLC but other uses offer hope
This article was originally published in Scrip
ArQule and Daiichi Sankyo have not completely lost hope for the c-Met inhibitor tivantinib (ARQ 197), but they have given up on treating patients who have non-small cell lung cancer (NSCLC) after the drug failed in the Phase III MARQUEE study to achieve statistical significance in the pivotal trial's primary endpoint of improvement in overall survival (OS).
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.